Future Market Insights6d
Global Venous Ulcer Treatment Market Value to reach USD 7.61 Billion by 2033, expanding at a 6.5% CAGR: FMI Report
The global venous ulcer treatment market, valued at USD 2.96 billion in 2023, is projected to experience robust growth, with ...
Monthly Prescribing Reference1d
Symvess, a Novel Treatment for Vascular Trauma, Gets FDA Approval
The single-use product is surgically implanted for arterial replacement and repair after a traumatic injury to the extremity.
FierceBiotech2d
FDA approves Humacyte’s off-the-shelf artery implant for vascular trauma repair
The FDA has granted a groundbreaking approval to Humacyte for its off-the-shelf, bioengineered blood vessel implant, designed ...
FDA approval propels North Carolina company's breakthrough treatment for trauma patients
A Durham company secured federal approval for its bioengineered tissue, which could become a revolutionary treatment for ...
Chronic Venous Ulceration Therapeutics Market in the 7MM is expected to grow by 2034, estimates DelveInsight
Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Chronic Venous Ulceration ...
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma
SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday?
Humacyte's Symvess earns FDA approval as a first-in-class bioengineered vascular solution for urgent arterial injury repair ...